Clinical Trial Update: First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation [EARLY_Phase 1]

View source ↗

Summary

First-in-human safety study of FX-322 in adults undergoing cochlear implantation has completed its early Phase 1 assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss

Drugs mentioned

• FX-322

Snippet

Sponsor: Frequency Therapeutics | Conditions: Hearing Loss | EARLY_Phase 1 | Status: COMPLETED